real-time news and commentary for investors
Thursday, Oct 24
Benchmark starts LeMaitre Vascular at Buy
- Benchmark initiates LeMaitre Vascular (LMAT +2%) at Buy.
- "The company's well-established position within the vascular surgeon community, and its focus on niche products that typically do not attract competition from the industry giants, give the company a bit of a home field advantage," analyst Jan Wald says, adding that "10%+ annual revenue growth and a $0.12 annual dividend provides investors with reasons to own the stock."
- Price target is $9, representing a 28% upside from Wednesday's close.